{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:02:15Z","timestamp":1766023335917,"version":"3.48.0"},"reference-count":56,"publisher":"e-Century Publishing Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/xfot8509","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T01:54:02Z","timestamp":1737510842000},"page":"127-140","source":"Crossref","is-referenced-by-count":0,"title":["Retinoic acid receptor-β deletion in a model of early pancreatic ductal adenocarcinoma (PDAC) tumorigenesis"],"prefix":"10.62347","volume":"15","author":[{"given":"Eduardo","family":"Mere Del Aguila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.trecan.2017.04.005","article-title":"Molecular events in the natural history of pancreatic cancer","volume":"3","author":"LE","year":"2017","unstructured":"Oldfield LE, Connor AA and Gallinger S. Molecular events in the natural history of pancreatic cancer. Trends Cancer 2017; 3: 336-346.","journal-title":"Trends Cancer"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.3390\/cancers12113096","article-title":"Pancreatic cancer (PDAC): introduction of evidence-based complementary measures into integrative clinical management","volume":"12","author":"Jentzsch","year":"2020","unstructured":"Jentzsch V, Davis JAA and Djamgoz MBA. Pancreatic cancer (PDAC): introduction of evidence-based complementary measures into integrative clinical management. Cancers (Basel) 2020; 12: 3096.","journal-title":"Cancers (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3322\/caac.21493","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives","year":"2018","unstructured":"Cives M and Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2018; 68: 471-487.","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of pancreatic cancer: global trends, etiology and risk factors","volume":"10","author":"Rawla","year":"2019","unstructured":"Rawla P, Sunkara T and Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 2019; 10: 10-27.","journal-title":"World J Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN and Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74: 12-49.","journal-title":"CA Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1073\/pnas.0908428107","article-title":"Mutant p53 drives metastasis and overcomes growth arrest\/senescence in pancreatic cancer","volume":"107","author":"Morton","year":"2010","unstructured":"Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Evans TR and Sansom OJ. Mutant p53 drives metastasis and overcomes growth arrest\/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 2010; 107: 246-251.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M and Maitra A. Pancreatic cancer: advances and challenges. Cell 2023; 186: 1729-1754.","journal-title":"Cell"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.pan.2016.05.393","article-title":"Pancreatic stellate cells regulate blood vessel density in the stroma of pancreatic ductal adenocarcinoma","volume":"16","author":"Di Maggio","year":"2016","unstructured":"Di Maggio F, Arumugam P, Delvecchio FR, Batista S, Lechertier T, Hodivala-Dilke K and Kocher HM. Pancreatic stellate cells regulate blood vessel density in the stroma of pancreatic ductal adenocarcinoma. Pancreatology 2016; 16: 995-1004.","journal-title":"Pancreatology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/cells10040847","article-title":"Dissecting FGF signalling to target cellular crosstalk in pancreatic cancer","volume":"10","author":"Carter","year":"2021","unstructured":"Carter EP, Coetzee AS, Tomas Bort E, Wang Q, Kocher HM and Grose RP. Dissecting FGF signalling to target cellular crosstalk in pancreatic cancer. Cells 2021; 10: 847.","journal-title":"Cells"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3322\/caac.21626","article-title":"Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma","volume":"70","author":"Grossberg","year":"2020","unstructured":"Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD and Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020; 70: 375-403.","journal-title":"CA Cancer J Clin"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"KP","year":"2009","unstructured":"Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J and Tuveson DA. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461.","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.3748\/wjg.v22.i9.2678","article-title":"Key players in pancreatic cancer-stroma interaction: cancer-associated fibroblasts, endothelial and inflammatory cells","volume":"22","author":"MF","year":"2016","unstructured":"Nielsen MF, Mortensen MB and Detlefsen S. Key players in pancreatic cancer-stroma interaction: cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol 2016; 22: 2678-2700.","journal-title":"World J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev-pathol-011110-130303","article-title":"Retinoids, retinoic acid receptors, and cancer","volume":"6","author":"Tang","year":"2011","unstructured":"Tang XH and Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 2011; 6: 345-364.","journal-title":"Annu Rev Pathol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3945\/an.115.009456","article-title":"Vitamins in pancreatic cancer: a review of underlying mechanisms and future applications","volume":"6","author":"Davis-Yadley","year":"2015","unstructured":"Davis-Yadley AH and Malafa MP. Vitamins in pancreatic cancer: a review of underlying mechanisms and future applications. Adv Nutr 2015; 6: 774-802.","journal-title":"Adv Nutr"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Gudas LJ. Retinoid metabolism: new insights. J Mol Endocrinol 2022; 69: T37-T49.","DOI":"10.1530\/JME-22-0082"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"158571","DOI":"10.1016\/j.bbalip.2019.158571","article-title":"The molecular aspects of absorption and metabolism of carotenoids and retinoids in vertebrates","volume":"1865","author":"Widjaja-Adhi","year":"2020","unstructured":"Widjaja-Adhi MAK and Golczak M. The molecular aspects of absorption and metabolism of carotenoids and retinoids in vertebrates. Biochim Biophys Acta Mol Cell Biol Lipids 2020; 1865: 158571.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"620941","DOI":"10.3389\/fendo.2021.620941","article-title":"Vitamin A and its multi-effects on pancreas: recent advances and prospects","volume":"12","author":"Zhou","year":"2021","unstructured":"Zhou Y, Wang H, Zhou J, Qiu S, Cai T, Li H, Shen Z, Hu Y, Ding B, Luo M, Huang R, Yan R, Xu W, He C, Zhang Y, Li F, Sun Z and Ma J. Vitamin A and its multi-effects on pancreas: recent advances and prospects. Front Endocrinol (Lausanne) 2021; 12: 620941.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mam.2014.12.003","article-title":"Retinoic acid receptors: from molecular mechanisms to cancer therapy","volume":"41","author":"di Masi","year":"2015","unstructured":"di Masi A, Leboffe L, De Marinis E, Pagano F, Cicconi L, Rochette-Egly C, Lo-Coco F, Ascenzi P and Nervi C. Retinoic acid receptors: from molecular mechanisms to cancer therapy. Mol Aspects Med 2015; 41: 1-115.","journal-title":"Mol Aspects Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/S0016-5085(97)70188-4","article-title":"Retinoic acid receptor beta regulates growth and differentiation in human pancreatic carcinoma cells","volume":"113","author":"Kaiser","year":"1997","unstructured":"Kaiser A, Herbst H, Fisher G, Koenigsmann M, Berdel WE, Riecken EO and Rosewicz S. Retinoic acid receptor beta regulates growth and differentiation in human pancreatic carcinoma cells. Gastroenterology 1997; 113: 920-929.","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/mc.22158","article-title":"Reduced retinoids and retinoid receptors’ expression in pancreatic cancer: a link to patient survival","volume":"54","author":"Bleul","year":"2015","unstructured":"Bleul T, Rühl R, Bulashevska S, Karakhanova S, Werner J and Bazhin AV. Reduced retinoids and retinoid receptors’ expression in pancreatic cancer: a link to patient survival. Mol Carcinog 2015; 54: 870-879.","journal-title":"Mol Carcinog"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.canlet.2006.11.019","article-title":"Tumor-suppressive activity of retinoic acid receptor-beta in cancer","volume":"253","author":"XC","year":"2007","unstructured":"Xu XC. Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett 2007; 253: 14-24.","journal-title":"Cancer Lett"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1146\/annurev-pharmtox-052120-104428","article-title":"Synthetic retinoids beyond cancer therapy","volume":"62","author":"Gudas","year":"2022","unstructured":"Gudas LJ. Synthetic retinoids beyond cancer therapy. Annu Rev Pharmacol Toxicol 2022; 62: 155-175.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/jnci\/89.9.624","article-title":"Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development","volume":"89","author":"XC","year":"1997","unstructured":"Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, Kurie JM, Hong WK and Lotan R. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst 1997; 89: 624-629.","journal-title":"J Natl Cancer Inst"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/hep.30193","article-title":"Retinoic acid receptor-β is downregulated in hepatocellular carcinoma and cirrhosis and its expression inhibits myosin-driven activation and durotaxis in hepatic stellate cells","volume":"69","author":"Cortes","year":"2019","unstructured":"Cortes E, Lachowski D, Rice A, Chronopoulos A, Robinson B, Thorpe S, Lee DA, Possamai LA, Wang H, Pinato DJ and Del Río Hernández AE. Retinoic acid receptor-β is downregulated in hepatocellular carcinoma and cirrhosis and its expression inhibits myosin-driven activation and durotaxis in hepatic stellate cells. Hepatology 2019; 69: 785-802.","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41389-023-00467-1","article-title":"Retinoic acid receptor β modulates mechanosensing and invasion in pancreatic cancer cells via myosin light chain 2","volume":"12","author":"Matellan","year":"2023","unstructured":"Matellan C, Lachowski D, Cortes E, Chiam KN, Krstic A, Thorpe SD and Del Río Hernández AE. Retinoic acid receptor β modulates mechanosensing and invasion in pancreatic cancer cells via myosin light chain 2. Oncogenesis 2023; 12: 23.","journal-title":"Oncogenesis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3892\/ijo.8.3.445","article-title":"Selective suppression of nuclear retinoic acid receptor beta gene expression in human pancreatic carcinomas","volume":"8","author":"Xu","year":"1996","unstructured":"Xu X, Stier U, Rosewicz S, Elnaggar A and Lotan R. Selective suppression of nuclear retinoic acid receptor beta gene expression in human pancreatic carcinomas. Int J Oncol 1996; 8: 445-451.","journal-title":"Int J Oncol"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Riecken EO and Rosewicz S. Retinoids in pancreatic cancer. Ann Oncol 1999; 10 Suppl 4: 197-200.","DOI":"10.1023\/A:1008319121622"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.1038\/s41467-020-18636-w","article-title":"Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer","volume":"11","author":"Kocher","year":"2020","unstructured":"Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN, Goulart MR, Hughes C, Imrali A, Roberts R, Pawula M, Houghton R, Lawrence C, Yogeswaran Y, Mousa K, Coetzee C, Sasieni P, Prendergast A and Propper DJ. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat Commun 2020; 11: 4841.","journal-title":"Nat Commun"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Koikawa K, Kibe S, Suizu F, Sekino N, Kim N, Manz TD, Pinch BJ, Akshinthala D, Verma A, Gaglia G, Nezu Y, Ke S, Qiu C, Ohuchida K, Oda Y, Lee TH, Wegiel B, Clohessy JG, London N, Santagata S, Wulf GM, Hidalgo M, Muthuswamy SK, Nakamura M, Gray NS, Zhou XZ and Lu KP. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell 2021; 184: 4753-4771, e4727.","DOI":"10.1016\/j.cell.2021.07.020"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.canlet.2013.12.006","article-title":"Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells","volume":"345","author":"Guan","year":"2014","unstructured":"Guan J, Zhang H, Wen Z, Gu Y, Cheng Y, Sun Y, Zhang T, Jia C, Lu Z and Chen J. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. Cancer Lett 2014; 345: 132-139.","journal-title":"Cancer Lett"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/MPA.0000000000000373","article-title":"Retinoic acid reduces stem cell-like features in pancreatic cancer cells","volume":"44","author":"Herreros-Villanueva M","year":"2015","unstructured":"Herreros-Villanueva M, Er TK and Bujanda L. Retinoic acid reduces stem cell-like features in pancreatic cancer cells. Pancreas 2015; 44: 918-924.","journal-title":"Pancreas"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pan.2019.11.006","article-title":"Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance","volume":"20","author":"Ariston Gabriel","year":"2020","unstructured":"Ariston Gabriel AN, Jiao Q, Yvette U, Yang X, Al-Ameri SA, Du L, Wang YS and Wang C. Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance. Pancreatology 2020; 20: 79-88.","journal-title":"Pancreatology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","article-title":"Organoid models of human and mouse ductal pancreatic cancer","volume":"160","author":"SF","year":"2015","unstructured":"Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Öhlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B, Creighton B, Wright K, Park Y, Morsink FH, Molenaar IQ, Borel Rinkes IH, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RG, Clevers H and Tuveson DA. Organoid models of human and mouse ductal pancreatic cancer. Cell 2015; 160: 324-338.","journal-title":"Cell"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/gene.10073","article-title":"A conditional floxed (loxP-flanked) allele for the retinoic acid receptor beta (RARbeta) gene","volume":"32","author":"Chapellier","year":"2002","unstructured":"Chapellier B, Mark M, Bastien J, Dierich A, LeMeur M, Chambon P and Ghyselinck NB. A conditional floxed (loxP-flanked) allele for the retinoic acid receptor beta (RARbeta) gene. Genesis 2002; 32: 91-94.","journal-title":"Genesis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"101331","DOI":"10.1016\/j.jbc.2021.101331","article-title":"A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying non-alcohol-associated fatty liver disease","volume":"297","author":"Tang","year":"2021","unstructured":"Tang XH, Melis M, Lu C, Rappa A, Zhang T, Jessurun J, Gross SS and Gudas LJ. A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying non-alcohol-associated fatty liver disease. J Biol Chem 2021; 297: 101331.","journal-title":"J Biol Chem"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.humpath.2013.10.008","article-title":"SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms","volume":"45","author":"Shroff","year":"2014","unstructured":"Shroff S, Rashid A, Wang H, Katz MH, Abbruzzese JL, Fleming JB and Wang H. SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms. Hum Pathol 2014; 45: 456-463.","journal-title":"Hum Pathol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1517\/17425250903032681","article-title":"The role of CYP26 enzymes in retinoic acid clearance","volume":"5","author":"Thatcher","year":"2009","unstructured":"Thatcher JE and Isoherranen N. The role of CYP26 enzymes in retinoic acid clearance. Expert Opin Drug Metab Toxicol 2009; 5: 875-886.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3390\/diagnostics10110982","article-title":"CYP26A1 is a novel biomarker for betel quid-related oral and pharyngeal cancers","volume":"10","author":"Chen","year":"2020","unstructured":"Chen PH, Chung CM, Wang YY, Huang HW, Huang B, Lee KW, Yuan SS, Wu CW, Lin LS and Chan LP. CYP26A1 is a novel biomarker for betel quid-related oral and pharyngeal cancers. Diagnostics (Basel) 2020; 10: 982.","journal-title":"Diagnostics (Basel)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3892\/or.2015.4042","article-title":"The retinoic acid-metabolizing enzyme CYP26A1 upregulates fascin and promotes the malignant behavior of breast carcinoma cells","volume":"34","author":"Osanai","year":"2015","unstructured":"Osanai M and Lee GH. The retinoic acid-metabolizing enzyme CYP26A1 upregulates fascin and promotes the malignant behavior of breast carcinoma cells. Oncol Rep 2015; 34: 850-858.","journal-title":"Oncol Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1186\/1756-0500-7-697","article-title":"Increased expression of the retinoic acid-metabolizing enzyme CYP26A1 during the progression of cervical squamous neoplasia and head and neck cancer","volume":"7","author":"Osanai","year":"2014","unstructured":"Osanai M and Lee GH. Increased expression of the retinoic acid-metabolizing enzyme CYP26A1 during the progression of cervical squamous neoplasia and head and neck cancer. BMC Res Notes 2014; 7: 697.","journal-title":"BMC Res Notes"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"5286820","DOI":"10.1155\/2022\/5286820","article-title":"CYP26A1 is a novel cancer biomarker of pancreatic carcinoma: evidence from integration analysis and in vitro experiments","volume":"2022","author":"Yu","year":"2022","unstructured":"Yu Y, Wang Y, Zou Y and Yu Y. CYP26A1 is a novel cancer biomarker of pancreatic carcinoma: evidence from integration analysis and in vitro experiments. Dis Markers 2022; 2022: 5286820.","journal-title":"Dis Markers"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s11033-022-08179-2","article-title":"Cellular retinol-binding protein 1: a therapeutic and diagnostic tumor marker","volume":"50","author":"Guo","year":"2023","unstructured":"Guo Z, Zhao Y, Wu Y, Zhang Y, Wang R, Liu W, Zhang C and Yang X. Cellular retinol-binding protein 1: a therapeutic and diagnostic tumor marker. Mol Biol Rep 2023; 50: 1885-1894.","journal-title":"Mol Biol Rep"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Colvin EK, Susanto JM, Kench JG, Ong VN, Mawson A, Pinese M, Chang DK, Rooman I, O’Toole SA, Segara D, Musgrove EA, Sutherland RL, Apte MV, Scarlett CJ and Biankin AV. Retinoid signaling in pancreatic cancer, injury and regeneration. PLoS One 2011; 6: e29075.","DOI":"10.1371\/journal.pone.0029075"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/978-3-319-09614-8_16","article-title":"Acetaldehyde and retinaldehyde-metabolizing enzymes in colon and pancreatic cancers","volume":"815","author":"Singh","year":"2015","unstructured":"Singh S, Arcaroli J, Thompson DC, Messersmith W and Vasiliou V. Acetaldehyde and retinaldehyde-metabolizing enzymes in colon and pancreatic cancers. Adv Exp Med Biol 2015; 815: 281-294.","journal-title":"Adv Exp Med Biol"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Xia J, Li S, Liu S and Zhang L. Aldehyde dehydrogenase in solid tumors and other diseases: potential biomarkers and therapeutic targets. MedComm (2020) 2023; 4: e195.","DOI":"10.1002\/mco2.195"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12022-015-9379-2","article-title":"Comparison of three Ki-67 index quantification methods and clinical significance in pancreatic neuroendocrine tumors","volume":"26","author":"Kroneman","year":"2015","unstructured":"Kroneman TN, Voss JS, Lohse CM, Wu TT, Smyrk TC and Zhang L. Comparison of three Ki-67 index quantification methods and clinical significance in pancreatic neuroendocrine tumors. Endocr Pathol 2015; 26: 255-262.","journal-title":"Endocr Pathol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1365-2559.1987.tb02609.x","article-title":"Vimentin: an evaluation of its role as a tumour marker","volume":"11","author":"Leader","year":"1987","unstructured":"Leader M, Collins M, Patel J and Henry K. Vimentin: an evaluation of its role as a tumour marker. Histopathology 1987; 11: 63-72.","journal-title":"Histopathology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1101\/gad.349358.122","article-title":"Roles of vimentin in health and disease","volume":"36","author":"Ridge","year":"2022","unstructured":"Ridge KM, Eriksson JE, Pekny M and Goldman RD. Roles of vimentin in health and disease. Genes Dev 2022; 36: 391-407.","journal-title":"Genes Dev"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/modpathol.2009.160","article-title":"Upregulation of vimentin and aberrant expression of E-cadherin\/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome","volume":"23","author":"Liu","year":"2010","unstructured":"Liu LK, Jiang XY, Zhou XX, Wang DM, Song XL and Jiang HB. Upregulation of vimentin and aberrant expression of E-cadherin\/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol 2010; 23: 213-224.","journal-title":"Mod Pathol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/bjc.2011.93","article-title":"Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas","volume":"104","author":"Handra-Luca","year":"2011","unstructured":"Handra-Luca A, Hong SM, Walter K, Wolfgang C, Hruban R and Goggins M. Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas. Br J Cancer 2011; 104: 1296-1302.","journal-title":"Br J Cancer"},{"key":"ref50","unstructured":"Schüssler MH, Skoudy A, Ramaekers F and Real FX. Intermediate filaments as differentiation markers of normal pancreas and pancreas cancer. Am J Pathol 1992; 140: 559-568."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.2353\/ajpath.2009.080545","article-title":"Epithelial-mesenchymal transition: a cancer researcher’s conceptual friend and foe","volume":"174","author":"Klymkowsky","year":"2009","unstructured":"Klymkowsky MW and Savagner P. Epithelial-mesenchymal transition: a cancer researcher’s conceptual friend and foe. Am J Pathol 2009; 174: 1588-1593.","journal-title":"Am J Pathol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/MPA.0b013e318269d281","article-title":"Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm","volume":"42","author":"Tanaka","year":"2013","unstructured":"Tanaka T, Kuroki T, Adachi T, Ono S, Hirabaru M, Soyama A, Kitasato A, Takatsuki M, Hayashi T and Eguchi S. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm. Pancreas 2013; 42: 488-493.","journal-title":"Pancreas"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/onc.2017.393","article-title":"SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer","volume":"37","author":"Zhou","year":"2018","unstructured":"Zhou H, Qin Y, Ji S, Ling J, Fu J, Zhuang Z, Fan X, Song L, Yu X and Chiao PJ. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer. Oncogene 2018; 37: 912-923.","journal-title":"Oncogene"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccr.2012.10.025","article-title":"Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma","volume":"22","author":"Kopp","year":"2012","unstructured":"Kopp JL, von Figura G, Mayes E, Liu FF, Dubois CL, Morris JP 4th, Pan FC, Akiyama H, Wright CV, Jensen K, Hebrok M and Sander M. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 22: 737-750.","journal-title":"Cancer Cell"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Tsai CY, Saito T, Sarangdhar M, Abu-El-Haija M, Wen L, Lee B, Yu M, Lipata DA, Manohar M, Barakat MT, Contrepois K, Tran TH, Theoret Y, Bo N, Ding Y, Stevenson K, Ladas EJ, Silverman LB, Quadro L, Anthony TG, Jegga AG and Husain SZ. A systems approach points to a therapeutic role for retinoids in asparaginase-associated pancreatitis. Sci Transl Med 2023; 15: eabn2110.","DOI":"10.1126\/scitranslmed.abn2110"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/1\/ajcr0160520.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:22Z","timestamp":1766023042000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/1\/ajcr0160520.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/xfot8509","relation":{},"ISSN":["2156-6976"],"issn-type":[{"type":"electronic","value":"2156-6976"}],"subject":[],"published":{"date-parts":[[2025]]}}}